

Ibrance® (palbociclib) - Expanded indications

- On April 4, 2019, the <u>FDA announced</u> the approval of <u>Pfizer's Ibrance (palbociclib)</u>, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men; or in combination with <u>Faslodex</u>[®] (fulvestrant) in patients with disease progression following endocrine therapy.
 - Previously, the first indication was approved only in postmenopausal women and the second indication was approved only in women.
- Breast cancer is rare in males with 2,670 cases of male breast cancer estimated in 2019. The
 majority of breast tumors in male patients express HRs. Men are more likely to be diagnosed at an
 older age, with a more advanced stage of disease.
- The expanded indications for breast cancer in men are based on limited data from post-marketing
 reports and real-world data from electronic health records showing the safety profile for men treated
 with Ibrance is consistent with the safety profile in women treated with Ibrance.
- The recommended dose of Ibrance is a 125 mg capsule taken orally once daily with food for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days.
 - For men treated with combination Ibrance plus aromatase inhibitor therapy, consider treatment with a luteinizing hormone-releasing hormone agonist according to current clinical practice standards.
 - Refer to prescribing information for Faslodex and specific aromatase inhibitors for further dosing recommendations.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.